Commercial DNA Testing May Cause Harm, Scientific Studies Show (If You Read Through to the Study Limitations at the End)
By Cecile Janssens,
Huffington Post
| 12. 22. 2014
Untitled Document
A year after the US Food and Drug Administration urged 23andMe to stop the marketing of its personal genome test in the United States, the world's largest direct-to-consumer genetics company relaunched the test in Canada and the United Kingdom.
"Find out how your genetics relate to things like abnormal blood clotting, cystic fibrosis or response to certain medications." [italics added] "Keep in mind that many conditions and traits are influenced by multiple factors. Our reports are intended for informational purposes only and do not diagnose disease or illness."
The UK website of 23andMe opens with clarifying statements about how the company wants us to see their renewed test. "The UK Medicines and Healthcare Products Regulatory Agency ... has determined that we're not a medical product, more an information product," says 23andMe's CEO Anne Wojcicki in The Guardian.
As it seems, 23andMe has relaunched its DNA test as the information service it was in the beginning: a service that offers a personalized exploration about what science knows about your genes, how they relate to your health and what...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...